Higher PE sounds sweet
But if Alcon was an earnings dog, why did the stock price go into orbit 150% and NVS got hammered by about an extra $15 after it gave up Alcon??
The lower price and no reduction in the dividend, and stock buy back and CEO forward guidance all look like a buy down this low.
Is the MS Drug news a good thing or way down the pike?
I am catching up all the news right now, still reading....
I would think that the NVS balance sheet might have shed some Alcon long term liabilities and debt?
But if Alcon was an earnings dog, why did the stock price go into orbit 150% and NVS got hammered by about an extra $15 after it gave up Alcon??
The lower price and no reduction in the dividend, and stock buy back and CEO forward guidance all look like a buy down this low.
Is the MS Drug news a good thing or way down the pike?
I am catching up all the news right now, still reading....
I would think that the NVS balance sheet might have shed some Alcon long term liabilities and debt?
All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.
Recent NVS News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 04:05:56 PM
- European stocks decline as investors await Big Tech earnings and Fed decision: DAX, CAC, FTSE100 • UK Market News • 04/28/2026 01:14:59 PM
- Novartis Secures Positive EU Backing for SMA Gene Therapy Itvisma • IH Market News • 04/24/2026 11:17:51 AM
- Novartis to broaden global health initiatives targeting underserved populations • IH Market News • 04/09/2026 11:12:41 AM
- Novartis agrees to acquire U.S. biotech company Excellergy in deal worth up to $2 billion • IH Market News • 03/27/2026 11:01:55 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/04/2026 09:30:35 PM
- European Shares Trade Mixed Following Eurozone Inflation Print: DAX, CAC, FTSE100 • UK Market News • 02/04/2026 02:11:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 11:52:05 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 11:51:07 AM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/04/2026 11:50:01 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/04/2026 11:45:53 AM
- European Markets Tick Higher as Earnings Roll In; UBS Steals the Spotlight: DAX, CAC, FTSE100 • UK Market News • 02/04/2026 10:13:05 AM
- Novartis CEO Says Expanded U.S. Production Limits Tariff Risk • IH Market News • 01/20/2026 11:00:22 AM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/12/2026 09:35:30 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • InvestorsHub NewsWire • 11/20/2025 02:00:00 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • GlobeNewswire Inc. • 11/20/2025 01:30:00 PM
- Novartis Expects 5–6% Annual Sales Growth Through 2030 • IH Market News • 11/20/2025 11:33:48 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2025 11:05:05 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/05/2025 09:33:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/03/2025 01:08:36 PM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/28/2025 09:26:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2025 04:12:41 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/28/2025 02:08:53 PM
- DAX, CAC, FTSE100, European stocks subdued as investors await central bank decisions • UK Market News • 10/28/2025 01:18:10 PM
- Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/28/2025 11:00:51 AM
